CNV-NT is under clinical development by BioMed Valley Discoveries and currently in Phase I for Fibrosarcoma. According to GlobalData, Phase I drugs for Fibrosarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CNV-NT LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CNV-NT overview

CNV-NT (BVD-CNV) is under development for the treatment of refractory solid tumor malignancies including sarcomas, leiomyosarcoma, chondrosarcoma, angiosarcoma, mullerian carcinoma, papillary thyroid carcinoma, breast cancer, serous ovarian cystadenocarcinoma, HPV-related squamous cell carcinoma of oropharyngeal cancer, metastatic osteosarcoma, liposarcoma endometrial carcinoma, adenocarcinoma, spindle cell sarcoma, NRAS-mutated melanoma, myxofibrosarcoma and recurrent chordoma. The drug candidate is administered through intratumoral route. The drug candidate is an attenuated single strain of Clostridium spores with the removal of the a-toxin gene.

BioMed Valley Discoveries overview

BioMed Valley Discoveries (BioMed) a subsidiary of Stowers Institute for Medical Research is a clinical stage biotechnology company which develops novel medicines for cancer. The company’s product portfolio includes CNV-NT an injection of clostridium novyi-NT spores to treat solid tumors, BVD-523 for the treatment of metastatic pancreatic cancer. It also provides BVD-723, a gamma inhibitor which counteracts cancer’s evasiveness and help boost an immune response to the disease, CD276 antibody-drug conjugate (ADC) used as a therapeutic agent to target multiple solid tumor. The company is developing therapies in the areas of oncology and immuno-oncology. BioMed is headquatered in Kansas, ?Missouri, the US.

For a complete picture of CNV-NT’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.